Novel (Atypical) Antidepressants

Heidi R. Bruty; Graham J. Emslie; Paul Croarkin

doi:10.1002/9781119958338.ch9

Novel (Atypical) Antidepressants

Heidi R. Bruty, Graham J. Emslie, Paul Croarkin

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

While the selective serotonin-reuptake inhibitors (SSRIs) are the first line treatment for juvenile depression and anxiety disorders, other novel antidepressants not chemically related to the SSRIs have also been prescribed to children and adolescents for unlabeled (non-FDA-approved) indications. These medications include bupropion, (Wellbutrin™), duloxetine Hydrochloride (Cymbalta™), mirtazapine (Remeron ™), trazodone (Desyrel™), venlafaxine (Effexor ™) and desvenlafaxine (Pristiq™). Their psychopharmacological profile and relevant pediatric studies are summarized in this chapter. Alternative or complimentary treatments (e.g. St. John's Wort, Omega-3 fatty acids, thyroid hormones, and S-Adenosyl Methionine (SAMe)) are also reviewed.

Original language	English (US)
Title of host publication	Pharmacotherapy of Child and Adolescent Psychiatric Disorders
Subtitle of host publication	Third Edition
Publisher	John Wiley and Sons
Pages	155-179
Number of pages	25
ISBN (Print)	9780470973769
DOIs	https://doi.org/10.1002/9781119958338.ch9
State	Published - Feb 17 2012

Keywords

Antidepressants
Anxiety
Depression
Pediatric Psychopharmacology

ASJC Scopus subject areas

General Medicine

Access to Document

10.1002/9781119958338.ch9

Cite this

@inbook{ebcbd142f8714924af9c521d5689b3ce,

title = "Novel (Atypical) Antidepressants",

abstract = "While the selective serotonin-reuptake inhibitors (SSRIs) are the first line treatment for juvenile depression and anxiety disorders, other novel antidepressants not chemically related to the SSRIs have also been prescribed to children and adolescents for unlabeled (non-FDA-approved) indications. These medications include bupropion, (Wellbutrin{\texttrademark}), duloxetine Hydrochloride (Cymbalta{\texttrademark}), mirtazapine (Remeron {\texttrademark}), trazodone (Desyrel{\texttrademark}), venlafaxine (Effexor {\texttrademark}) and desvenlafaxine (Pristiq{\texttrademark}). Their psychopharmacological profile and relevant pediatric studies are summarized in this chapter. Alternative or complimentary treatments (e.g. St. John's Wort, Omega-3 fatty acids, thyroid hormones, and S-Adenosyl Methionine (SAMe)) are also reviewed.",

keywords = "Antidepressants, Anxiety, Depression, Pediatric Psychopharmacology",

author = "Bruty, {Heidi R.} and Emslie, {Graham J.} and Paul Croarkin",

year = "2012",

month = feb,

day = "17",

doi = "10.1002/9781119958338.ch9",

language = "English (US)",

isbn = "9780470973769",

pages = "155--179",

booktitle = "Pharmacotherapy of Child and Adolescent Psychiatric Disorders",

publisher = "John Wiley and Sons",

}

TY - CHAP

T1 - Novel (Atypical) Antidepressants

AU - Bruty, Heidi R.

AU - Emslie, Graham J.

AU - Croarkin, Paul

PY - 2012/2/17

Y1 - 2012/2/17

N2 - While the selective serotonin-reuptake inhibitors (SSRIs) are the first line treatment for juvenile depression and anxiety disorders, other novel antidepressants not chemically related to the SSRIs have also been prescribed to children and adolescents for unlabeled (non-FDA-approved) indications. These medications include bupropion, (Wellbutrin™), duloxetine Hydrochloride (Cymbalta™), mirtazapine (Remeron ™), trazodone (Desyrel™), venlafaxine (Effexor ™) and desvenlafaxine (Pristiq™). Their psychopharmacological profile and relevant pediatric studies are summarized in this chapter. Alternative or complimentary treatments (e.g. St. John's Wort, Omega-3 fatty acids, thyroid hormones, and S-Adenosyl Methionine (SAMe)) are also reviewed.

AB - While the selective serotonin-reuptake inhibitors (SSRIs) are the first line treatment for juvenile depression and anxiety disorders, other novel antidepressants not chemically related to the SSRIs have also been prescribed to children and adolescents for unlabeled (non-FDA-approved) indications. These medications include bupropion, (Wellbutrin™), duloxetine Hydrochloride (Cymbalta™), mirtazapine (Remeron ™), trazodone (Desyrel™), venlafaxine (Effexor ™) and desvenlafaxine (Pristiq™). Their psychopharmacological profile and relevant pediatric studies are summarized in this chapter. Alternative or complimentary treatments (e.g. St. John's Wort, Omega-3 fatty acids, thyroid hormones, and S-Adenosyl Methionine (SAMe)) are also reviewed.

KW - Antidepressants

KW - Anxiety

KW - Depression

KW - Pediatric Psychopharmacology

UR - http://www.scopus.com/inward/record.url?scp=84886854724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886854724&partnerID=8YFLogxK

U2 - 10.1002/9781119958338.ch9

DO - 10.1002/9781119958338.ch9

M3 - Chapter

AN - SCOPUS:84886854724

SN - 9780470973769

SP - 155

EP - 179

BT - Pharmacotherapy of Child and Adolescent Psychiatric Disorders

PB - John Wiley and Sons

ER -

Novel (Atypical) Antidepressants

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this